CL2019002777A1 - Compuestos que inhiben la proteína mcl-1. - Google Patents
Compuestos que inhiben la proteína mcl-1.Info
- Publication number
- CL2019002777A1 CL2019002777A1 CL2019002777A CL2019002777A CL2019002777A1 CL 2019002777 A1 CL2019002777 A1 CL 2019002777A1 CL 2019002777 A CL2019002777 A CL 2019002777A CL 2019002777 A CL2019002777 A CL 2019002777A CL 2019002777 A1 CL2019002777 A1 CL 2019002777A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- mcl
- inhibit
- protein
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Abstract
EN LA PRESENTE SE PROVEEN INHIBIDORES DE LA PROTEÍNA LEUCEMIA DE CÉLULAS MIELOIDES 1 (MCL- 1), MÉTODOS PARA SU PREPARACIÓN, COMPOSICIONES FARMACÉUTICAS RELACIONADAS, Y MÉTODOS DE USO DE ESTO. POR EJEMPLO, EN LA PRESENTE SE PROVEEN COMPUESTOS DE FÓRMULA 1, O UN ESTEREOISOMERO DE ESTOS; Y SALES FARMACÉUTICAMENTE ACEPTABLES DE ESTOS Y COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN LOS COMPUESTOS. LOS COMPUESTOS Y COMPOSICIONES PROVISTAS EN LA PRESENTE PUEDEN USARSE, POR EJEMPLO, EN EL TRATAMIENTO DE ENFERMEDADES O AFECCIONES, COMO CÁNCER.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762479230P | 2017-03-30 | 2017-03-30 | |
US201762479171P | 2017-03-30 | 2017-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2019002777A1 true CL2019002777A1 (es) | 2019-12-20 |
Family
ID=61972255
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2019002777A CL2019002777A1 (es) | 2017-03-30 | 2019-09-27 | Compuestos que inhiben la proteína mcl-1. |
Country Status (33)
Country | Link |
---|---|
US (5) | US10300075B2 (es) |
EP (1) | EP3601297B9 (es) |
JP (2) | JP6453507B2 (es) |
KR (1) | KR102372322B1 (es) |
CN (1) | CN110691784B (es) |
AU (2) | AU2018244349B2 (es) |
BR (1) | BR112019020459B1 (es) |
CA (1) | CA3057882A1 (es) |
CL (1) | CL2019002777A1 (es) |
CO (1) | CO2019011762A2 (es) |
CR (1) | CR20190489A (es) |
DK (1) | DK3601297T5 (es) |
ES (1) | ES2940641T3 (es) |
FI (1) | FI3601297T3 (es) |
HR (1) | HRP20221412T2 (es) |
HU (1) | HUE060919T2 (es) |
IL (1) | IL269603B (es) |
JO (1) | JOP20190229B1 (es) |
LT (1) | LT3601297T (es) |
MX (1) | MX2019011693A (es) |
NZ (1) | NZ757606A (es) |
PE (1) | PE20200335A1 (es) |
PH (1) | PH12019502245A1 (es) |
PL (1) | PL3601297T3 (es) |
PT (1) | PT3601297T (es) |
RS (1) | RS63892B9 (es) |
SA (1) | SA519410222B1 (es) |
SG (1) | SG11201908945RA (es) |
SI (1) | SI3601297T1 (es) |
TW (1) | TWI685493B (es) |
UA (1) | UA124784C2 (es) |
UY (1) | UY37656A (es) |
WO (1) | WO2018183418A1 (es) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102611446B1 (ko) | 2017-01-20 | 2023-12-06 | 아르커스 바이오사이언시즈 인코포레이티드 | 암-관련 장애의 치료를 위한 아졸로피리미딘 |
JOP20180029A1 (ar) | 2017-03-30 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب حلقي غير متجانس |
JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Mcl−1タンパク質を阻害する化合物 |
PE20200008A1 (es) | 2017-03-30 | 2020-01-06 | Hoffmann La Roche | Isoquinolinas como inhibidores de hpk1 |
US11364248B2 (en) * | 2017-08-18 | 2022-06-21 | Amgen Inc. | Compounds that inhibit Mcl-1 protein |
EP3676270A1 (en) | 2017-08-29 | 2020-07-08 | Amgen Inc. | Macrocyclic compounds that inhibit mcl-1 protein |
US11301560B2 (en) * | 2018-02-09 | 2022-04-12 | Bolster, Inc | Real-time detection and blocking of counterfeit websites |
US11271966B2 (en) * | 2018-02-09 | 2022-03-08 | Bolster, Inc | Real-time detection and redirecton from counterfeit websites |
KR20200121337A (ko) | 2018-02-16 | 2020-10-23 | 아르커스 바이오사이언시즈 인코포레이티드 | 아졸로피리미딘 화합물의 투여 |
US11274105B2 (en) | 2018-03-05 | 2022-03-15 | Amgen Inc. | Alpha-hydroxy phenylacetic acid pharmacophore or bioisostere Mcl-1 protein antagonists |
BR112020021648A2 (pt) | 2018-05-14 | 2021-01-26 | Gilead Sciences, Inc. | inibidores de mcl-1 |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
CN113166173A (zh) | 2018-11-09 | 2021-07-23 | 普莱鲁德疗法有限公司 | 作为骨髓细胞白血病1(mcl-1)蛋白抑制剂的螺-磺酰胺衍生物 |
CN112867722B (zh) * | 2019-01-18 | 2022-09-23 | 苏州亚盛药业有限公司 | 作为mcl-1抑制剂的大螺环醚(macrocyclic spiroethers) |
WO2020151738A1 (en) * | 2019-01-23 | 2020-07-30 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrrazoles as mcl-1 inhibitors |
WO2020236825A2 (en) | 2019-05-20 | 2020-11-26 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
CA3142513A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
CA3144558A1 (en) | 2019-07-09 | 2021-01-14 | Janssen Pharmaceutica Nv | Macrocyclic spirocycle derivatives as mcl-1 inhibitors |
AU2020365113A1 (en) | 2019-10-18 | 2022-04-07 | Forty Seven, Inc. | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
MX2022005123A (es) | 2019-10-31 | 2022-05-30 | Forty Seven Inc | Tratamiento basado en anti-cd47 y anti-cd20 para cancer hematologico. |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
KR20220105661A (ko) | 2019-11-26 | 2022-07-27 | 길리애드 사이언시즈, 인코포레이티드 | Mcl1 억제제를 제조하기 위한 방법 및 중간체 |
CA3165735A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
BR112022014623A2 (pt) | 2020-02-14 | 2022-09-13 | Jounce Therapeutics Inc | Anticorpos e proteínas de fusão que se ligam a ccr8 e usos dos mesmos |
JP2021161114A (ja) | 2020-03-31 | 2021-10-11 | アムジエン・インコーポレーテツド | Mcl−1化合物のメチル化 |
US20230212191A1 (en) * | 2020-04-16 | 2023-07-06 | Prelude Therapeutics, Incorporated | Spiro-sulfonimidamide derivatives as inhibitors of myeloid cell leukemia-1 (mcl-1) protein |
US20230039553A1 (en) | 2020-05-01 | 2023-02-09 | Gilead Sciences, Inc. | Cd73 compounds |
EP4146622A1 (en) | 2020-05-06 | 2023-03-15 | Amgen Inc. | Synthesis of sulfonamide intermediates |
WO2021225823A1 (en) | 2020-05-06 | 2021-11-11 | Amgen Inc. | Synthesis of vinylic protected alcohol intermediates |
TW202208342A (zh) | 2020-05-06 | 2022-03-01 | 美商安進公司 | 乙烯基環丁基中間體之合成 |
TWI827924B (zh) | 2020-05-06 | 2024-01-01 | 美商安進公司 | 大環Mcl-1抑制劑中間體的閉環合成 |
CN115461332A (zh) * | 2020-05-06 | 2022-12-09 | 安进公司 | 乙烯醇中间体的合成 |
IL298157A (en) * | 2020-05-13 | 2023-01-01 | Prelude Therapeutics Inc | History of spirosulfonamide as an inhibitor of myeloid cell leukemia protein 1 (mcl-1) |
JP2023528965A (ja) * | 2020-06-10 | 2023-07-06 | ヤンセン ファーマシューティカ エヌ.ベー. | Mcl-1の阻害剤としての大環状2-アミノ-3-フルオロ-ブタ-3-エナミド |
JP2022039996A (ja) | 2020-08-26 | 2022-03-10 | アムジエン・インコーポレーテツド | Mcl-1阻害剤処方物 |
KR20230058694A (ko) | 2020-09-03 | 2023-05-03 | 암젠 인크 | 친핵성 방향족 치환에 의한 디올 탈대칭화 |
EP4247783A1 (en) * | 2020-11-19 | 2023-09-27 | Gilead Sciences, Inc. | Processes and intermediates for preparing macrocyclic mcl1 inhibitors |
US20240042051A1 (en) | 2020-11-24 | 2024-02-08 | Francesca Rocchetti | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
CN116745258A (zh) | 2020-11-25 | 2023-09-12 | 安进公司 | 醛的对映选择性烯基化 |
KR20230121806A (ko) | 2020-12-17 | 2023-08-21 | 얀센 파마슈티카 엔.브이. | Mcl-1의 억제제로서의 마크로사이클릭 분지형 3-플루오로-부트-3-엔아미드 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
JP2024516641A (ja) | 2021-04-26 | 2024-04-16 | ヤンセン ファーマシューティカ エヌ.ベー. | Mcl-1阻害剤としての大環状2-アリルテトラヒドロフラン |
TW202313094A (zh) | 2021-05-18 | 2023-04-01 | 美商基利科學股份有限公司 | 使用FLT3L—Fc融合蛋白之方法 |
TW202317200A (zh) | 2021-06-11 | 2023-05-01 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗體藥物接合物之組合 |
US11957693B2 (en) | 2021-06-11 | 2024-04-16 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-cancer agents |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11926628B2 (en) | 2021-06-23 | 2024-03-12 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
AU2022298639A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023057484A1 (en) | 2021-10-06 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
AU2022376954A1 (en) | 2021-10-29 | 2024-05-02 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023088894A1 (en) | 2021-11-16 | 2023-05-25 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-but-3-enamides as inhibitors of mcl-1 |
WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
WO2023150249A1 (en) | 2022-02-04 | 2023-08-10 | Amgen Inc. | Crystalline forms of an mcl-1 inhibitor |
WO2023150250A1 (en) | 2022-02-04 | 2023-08-10 | Amgen Inc. | Crystalline salt and solvate forms of murizatoclax (amg 397) |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
EP2134684B1 (en) | 2007-04-16 | 2017-08-02 | AbbVie Inc. | 7-substituted indole as mcl-1 inhibitors |
US20130035304A1 (en) | 2010-01-29 | 2013-02-07 | Walensky Loren D | Small molecules for the modulation of mcl-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders |
US20130048221A1 (en) | 2011-08-31 | 2013-02-28 | Avery Dennison Corporation | Adhesive Acrylate-Olefin Copolymers, Methods for Producing Same and Compositions Utilizing Same |
WO2013052943A2 (en) | 2011-10-06 | 2013-04-11 | The Regents Of The University Of Michgian | Small molecule inhibitors of mcl-1 and uses thereof |
EP2831067B1 (en) | 2012-03-29 | 2017-11-01 | The Regents Of The University Of Michigan | Small molecule inhibitors of mcl-1 and uses thereof |
EP3122353B1 (en) * | 2014-03-27 | 2020-10-28 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
US11306107B2 (en) * | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
JP6786892B2 (ja) | 2016-06-09 | 2020-11-18 | 富士ゼロックス株式会社 | サーバ装置、情報処理システム及びプログラム |
JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Mcl−1タンパク質を阻害する化合物 |
US11364248B2 (en) | 2017-08-18 | 2022-06-21 | Amgen Inc. | Compounds that inhibit Mcl-1 protein |
EP3676270A1 (en) | 2017-08-29 | 2020-07-08 | Amgen Inc. | Macrocyclic compounds that inhibit mcl-1 protein |
-
2018
- 2018-03-27 JP JP2018059341A patent/JP6453507B2/ja active Active
- 2018-03-28 SI SI201830809T patent/SI3601297T1/sl unknown
- 2018-03-28 EP EP18717811.6A patent/EP3601297B9/en active Active
- 2018-03-28 KR KR1020197029091A patent/KR102372322B1/ko active IP Right Grant
- 2018-03-28 CR CR20190489A patent/CR20190489A/es unknown
- 2018-03-28 PE PE2019001963A patent/PE20200335A1/es unknown
- 2018-03-28 UA UAA201910703A patent/UA124784C2/uk unknown
- 2018-03-28 JO JOP/2019/0229A patent/JOP20190229B1/ar active
- 2018-03-28 DK DK18717811.6T patent/DK3601297T5/da active
- 2018-03-28 HR HRP20221412TT patent/HRP20221412T2/hr unknown
- 2018-03-28 AU AU2018244349A patent/AU2018244349B2/en active Active
- 2018-03-28 CA CA3057882A patent/CA3057882A1/en active Pending
- 2018-03-28 SG SG11201908945R patent/SG11201908945RA/en unknown
- 2018-03-28 PL PL18717811.6T patent/PL3601297T3/pl unknown
- 2018-03-28 ES ES18717811T patent/ES2940641T3/es active Active
- 2018-03-28 MX MX2019011693A patent/MX2019011693A/es unknown
- 2018-03-28 LT LTEPPCT/US2018/024723T patent/LT3601297T/lt unknown
- 2018-03-28 FI FIEP18717811.6T patent/FI3601297T3/fi active
- 2018-03-28 NZ NZ757606A patent/NZ757606A/en unknown
- 2018-03-28 WO PCT/US2018/024723 patent/WO2018183418A1/en unknown
- 2018-03-28 RS RS20230036A patent/RS63892B9/sr unknown
- 2018-03-28 PT PT187178116T patent/PT3601297T/pt unknown
- 2018-03-28 BR BR112019020459-8A patent/BR112019020459B1/pt active IP Right Grant
- 2018-03-28 HU HUE18717811A patent/HUE060919T2/hu unknown
- 2018-03-28 US US15/938,001 patent/US10300075B2/en active Active
- 2018-03-28 CN CN201880035818.3A patent/CN110691784B/zh active Active
- 2018-03-30 TW TW107111110A patent/TWI685493B/zh active
- 2018-04-02 UY UY0001037656A patent/UY37656A/es unknown
- 2018-12-11 JP JP2018231352A patent/JP6629419B2/ja active Active
-
2019
- 2019-03-11 US US16/297,904 patent/US10500213B2/en active Active
- 2019-08-22 US US16/547,747 patent/US10632128B2/en active Active
- 2019-09-24 IL IL269603A patent/IL269603B/en unknown
- 2019-09-27 CL CL2019002777A patent/CL2019002777A1/es unknown
- 2019-09-27 PH PH12019502245A patent/PH12019502245A1/en unknown
- 2019-09-30 SA SA519410222A patent/SA519410222B1/ar unknown
- 2019-10-24 CO CONC2019/0011762A patent/CO2019011762A2/es unknown
-
2020
- 2020-02-06 US US16/783,269 patent/US10821115B2/en active Active
- 2020-09-23 US US17/029,249 patent/US11224601B1/en active Active
-
2021
- 2021-01-15 AU AU2021200233A patent/AU2021200233A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019002777A1 (es) | Compuestos que inhiben la proteína mcl-1. | |
CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
UY38221A (es) | Inhibidores de proteínas ras con g12c mutantes | |
CL2019000821A1 (es) | Composiciones, métodos y usos para inhibir la actividad arginasa. (divisional solicitud 201801134) | |
UY38001A (es) | Compuestos que inhiben las proteínas ras mutantes g12c | |
ECSP22018571A (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
ECSP21038390A (es) | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de su uso como inhibidores de la cinasa atr | |
CO2020004977A2 (es) | Compuestos bicíclicos para su uso como inhibidores de la ripi quinasa | |
CL2018003121A1 (es) | Inhibidores del potenciador del homólogo zeste 2. | |
CO2019002523A2 (es) | Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica | |
UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
UY36758A (es) | Inhibidores del potenciador del homólogo zeste 2 | |
CL2021001198A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) | |
ECSP18056196A (es) | Derivados de indano | |
UY38133A (es) | Nuevos inhibidores de cdk8/19 | |
EA201992303A1 (ru) | СОЕДИНЕНИЯ, КОТОРЫЕ ИНГИБИРУЮТ БЕЛОК Mcl-1 | |
CL2020002398A1 (es) | Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd") | |
CR20150593A (es) | Potenciador de inhibidores del homólogo de zeste |